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Introduction
Primary cutaneous CD30+ lympho-
proliferative disorders (LPDs) are the second
most common group of primary cutaneous
T-cell lymphomas (CTCLs), accounting for
approxi-mately 25-30% of CTCLs. The
spectrum of LPDs includes lymphomatoid
papulosis (LyP), primary cutaneous anaplastic
large cell lymphoma (C-ALCL) and borderline
cases [1-9]. 
LyP is a chronic skin disease, characterized by
recurrent and self-healing papulonodular skin
lesions, which contain atypical lymphocytes
intermingled with a mixed inflammatory infiltrate
[1, 4-10].
C-ALCL is a lymphoma composed of large
cells with an anaplastic, pleomorphic or
immunoblastic cytomorphology. Most (more
than 75%) neoplastic cells express the CD30
antigen. There is also no clinical evidence or
history of LyP, mycosis fungoides (MF) or
another type of CTCL [1, 4-9, 11].
The term “borderline lesions” refers to cases
where histological features are similar to LyP, but
clinically behave as C-ALCL, or to cases where
histological features are typical for C-ALCL, but
clinically behave as LyP. Clinical examinations
during further follow-up will generally allow for
making a diagnosis of LyP or C-ALCL [4, 6, 8, 9].
It is now generally accepted that C-ALCL and
LyP represent two ends of a spectrum of LPDs
and morphological criteria alone are often
insufficient to differentiate between these two
entities. The clinical appearance and course are
used as decisive criteria for the definitive diagnosis
and choice of treatment [4, 6, 8].
Material and methods 
Clinical data were retrieved from the archive
files of the Department of Oncology.
The original skin biopsies that had been fixed
in formaldehyde solution, embedded in paraffin
and stained with haematoxylin and eosin were
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reviewed. Subsequent slides were immunostained
with antibodies CD20, CD79α, CD45RO, CD5,
CD3, CD2, CD4, CD8, CD30, granzyme B,
ALK-1, EMA, CD15, CD68, CD56, S100, bcl-2.
DNA extraction: Formalin-fixed and
paraffin-embedded (FF/PE) samples were
deparaffinized and DNA was extracted using
the QIAamp DNA Mini Kit (Qiagen GmbH,
Hilden, Germany) according to the manu-
facturer’s instructions. T-cell clonality was
determined by a PCR-based assay for TCRG gene
rearrangement analysis according to previously
described protocols [12, 13]. Primers JG12, VG11,
VG101 were used [12]. Amplifications were
performed with an annealing temperature of 55°C;
the number of cycles was 35 [13]. PCR products
were analyzed by electrophoresis on 10%
polyacrylamide gel. Two samples were analyzed
in triplicate.
Clinical findings
A 46-year old male first reported to
the Department of Oncology due to lesions
confined to the skin involving his buttocks and
right hip, persisting for one month. Physical
examination demonstrated several infiltrative skin
lesions on the right buttock, the largest one
measuring approximately 5 cm, with an elevated
border and central ulceration measuring 1.5 cm. On
the left back and buttock, small papules were seen. 
On the right hip, pale pink, flat lesions measuring
1 × 1.5 cm were observed. 
After two courses of chemotherapy COP
(cyclophosphamide + vincristine + prednisone),
complete regression of the lesions situated on
the left buttock was achieved, but the lesions
involving the right hip progressed. In addition, new
lesions developed on the right thigh. As
a consequence of disease progression, the treatment
was switched to the ABVD chemotherapy protocol
(doxorubicin + bleomycin + vinblastine +
dacarbazine) and radiotherapy of the right buttock
(4200 cGy/14fr/200 KV). In view of the fact that
new lesions appeared on the chest and back in
the course of the above treatment the patient
received three courses of CTX + VP + MTX +
Adr (cyclophosphamide + vindesine/ platinum +
methotrexate + Adriamycin) and right back field
radiotherapy (2400 cGy/6 fr/200 KV). At the end
of this treatment, all the skin lesions regressed. 
One year later, two new skin lesions appeared
on the abdomen, measuring approximately 2 cm
each, which regressed after administration
of topical steroids only. 
After nine years without any new lesions, new
rapidly growing skin lesions appeared. Physical
examination revealed two tumours: a firm, dark red
tumour, partially ulcerated, with indistinct border,
situated on the abdomen and measuring 
5 × 6 cm. The other tumour, with a similar
appearance, was located on the left buttock and
measured 2 × 3 cm. Radiotherapy of the lesion
involving the abdomen (4000 cGy/20 fr/250 KV)
resulted in almost complete regression. A new lesion
appeared near the right clavicle, measuring 1 cm.
The patient received three courses of chemotherapy
(chlorambucil + prednisone). The lesion near
the clavicle regressed, but the infiltrate on the left
buttock remained stable. Radiotherapy of this lesion
(4000 cGy/20 fr/250 KV) resulted in complete
regression, but new lesions nearby measuring 
2.5 × 2.0 cm appeared (Fig. 1). The patient was
referred for radiotherapy.
Histopathological findings
The first biopsy taken from the skin lesion on
the buttock revealed a dense irregular lymphoid
infiltrate involving the dermis and subcutaneous
fat. The epidermis was spared. The infiltrate
consisted of large atypical lymphocytes admixed
with small lymphocytes. Some of the atypical cells
showed morphology of anaplastic cells with
round, oval or irregularly shaped nuclei and
abundant cytoplasm. Prominent nucleoli were
evident in some cells. Mitotic activity in these cells
was low.
In biopsy taken subsequently from the same
lesion, a denser atypical lymphoid infiltrate was
seen in the dermis and subcutaneous tissue. 
The epidermis was partially ulcerated (Fig. 2).
Cohesive sheets of atypical cells, showing
anaplastic morphology, admixed with numerous
small lymphocytes, were centred on skin adnexa.
Mitotic rate was higher (approximately 17 mitoses
per 10 high-power fields). The following biopsy
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Fig. 1. The larger erythematous area on the left buttock
represents regressed tumour after radiotherapy. On the left
– two newly developed intradermally located nodules
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taken from the skin lesion on the right thigh in
the course of therapy revealed lymphoid infiltrates
located mainly in the reticular dermis and
subcutaneous tissue. Irregular infiltrates centred
on skin adnexa were similar to those observed in
previous biopsies. 
The last biopsy taken from the skin lesion on
the abdomen showed a diffuse lymphoid infiltrate
in the dermis, sparing the epidermis. Irregular
infiltrates were composed mainly of large atypical
lymphocytes, showing anaplastic morphology and
admixed with only a few small lymphocytes.
Mitotic rate in large cells was high (approximately
41 mitoses per 10 high-power fields) (Fig. 3). The
number of atypical cells was significantly higher as
compared to the previous specimens, but
the morphology was the same. In none of those
biopsies was a granulocytic infiltrate found.
The majority of the large cells expressed
antigens CD45RO and CD5, but only some
of these cells expressed antigens CD3, CD2, CD8
and granzyme B. Neoplastic cells did not express
CD4, ALK-1, CD15 and CD56. CD30 was
positive in only 40-50% of the large cells in
the biopsy taken from the abdomen (Fig. 4), and
in 30-40% of the cell originating from the biopsy
taken from the buttock. Antigens CD20, CD79α
and bcl-2 revealed only a small amount of admixed
B lymphocytes. The reaction with CD68 showed
numerous histiocytes admixed with atypical cells.
There were also a few S100-positive cells. Small
lymphocytes admixed with atypical cells expressed
CD45RO, CD3, CD5, CD8 and CD2.
Two specimens were selected for performing
the T-cell clonality analysis: the second biopsy
taken from the skin lesion on the buttock and
Fig. 2. Partially ulcerated skin with dense lymphoid
infiltrate. HE, original magnification 50 ×
Fig. 3. Numerous large atypical lymphocytes with anaplastic
morphology. Numerous mitotic figures and dissection
of collagen are seen. HE, original magnification 400 ×
Fig. 4. Large atypical cells show expression of CD30
antigen. Original magnification 400 ×
Fig. 5. T-cell clonality analysis: 1 – material from the second
biopsy taken from the skin lesion on the buttock, 
2 – material from the last biopsy taken from the skin lesion
on the abdomen; M – size standard, MC – monoclonal
control, PC – polyclonal control, 0 – control without DNA
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the last biopsy taken from the skin lesion on
the abdomen. In the first material, the analysis
showed one discrete band on a smear pattern that
corresponded to a clonal T-cell population and
a coexisting polyclonal background.
The second material revealed an oligoclonal
population of T-cells with a strong dominant
clone on a very weak polyclonal background.
Both tissues (the present and retrospective tissue
sample) showed a dominant equal-sized band that
may indicate a common origin of the T-cell popu-
lation (Fig. 5).
Finally a diagnosis of LPD, borderline between
Lyp and C-ALCL, was made.
Discussion 
Lesions in LyP occur often as crops of papules
and/or nodules with a propensity for clustering.
They regress spontaneously within 3 to 12 weeks,
and may persist behind superficial scars or
hyperpigmentation. New lesions can appear in
the same or different locations. Sometimes larger
lesions develop (usually not exceeding 2 cm in
diameter), and it can take months before they
disappear [2, 4-9]. 
C-ALCL typically presents as a solitary, firm,
large, often ulcerated tumour, which grows rapidly.
Approximately 20% of patients have multifocal
disease (two or more lesions at different anatomic
sites). Occasionally, satellites in the vicinity
of a larger tumour are found or grouped nodules or
papules. Patients with C-ALCL may also present
with widespread papular eruptions, similar to LyP
[10]. Skin lesions can show features of partial or
complete remission, similar to LyP. Cutaneous
relapses are common. Extracutaneous spread occurs
in approximately 10% of patients; most commonly,
regional lymph nodes are involved [2, 4-10, 14].
According to some authors, skin relapses in
C-ALCL most often (in 75%) occur within 12 to 
24 months [15]. Only in the material of the Dutch
Cutaneous Lymphoma Group did disease-free
survival range from 1 to 192 months [2]. LyP tends
to last for years (from a few months to more than
40 years) [4, 6]. 
From the clinical point of view, differential
diagnosis between C-ALCL and LyP can be
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Table I. Morphological features useful in differential diagnosis between LyP and C-ALCL
LYP C C-ALCL
• Absence or only limited involvement • The infiltrate involves deeper dermis 
of subcutaneous fat [9] and subcutaneous fat
• Morphology of neoplastic cells closer to that • More numerous neoplastic cells
of immunoblasts [5] (but strict criteria are not given) 
•  Inflammatory infiltrate intermingled with large •  Neoplastic cells more often show anaplastic
cells [5] morphology
• Neutrophils found in most sections [10] • Inflammatory infiltrate, mainly small lymphocytes,
is found at the periphery of the lesion [5]
Table II. Differential diagnosis of LPDs [2, 4, 6, 7, 9, 10]
LYMPHOMAS REACTIVE CHANGES
• CD30+ cutaneous lymphoma secondary • Parasitic (e.g. scabies), viral (e.g. Herpes simplex, 
to mycosis fungoides (MF) varicella zoster, parapoxviruses, poxviruses) 
• Systemic ALCL with secondary skin involvement and bacterial (tuberculosis) infections
• Extranodal NK/T – cell lymphoma, nasal type • Arthropod bite reactions
• Primary cutaneous aggressive epidermotropic • PLEVA
CD8+ cytotoxic T-cell lymphoma • Atopic dermatitis
• Pagetoid reticulosis • Drug-induced reactions
• CD30+ cutaneous B-cell lymphomas
• Hodgkin’s lymphoma
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difficult, even if not impossible, particularly when
the patient presents with large tumours (several
cm), which can persist for months until
spontaneous regression occurs. It is still a matter
of debate whether such lesions should be
considered as part of the spectrum of clinical
manifestation of LyP or whether those tumours
represent concurrent C-ALCL [7].
The histological features in LyP are extremely
variable and depend on the stage of the lesion and
disease. Three histological subtypes have been
described, which represent a spectrum with
overlapping features. In type C lesions, mostly
resembling C-ALCL large CD30+ cells form
a monotonous population or large clusters with
relatively few admixed inflammatory cells. In
C-ALCL, there is a diffuse infiltrate with cohesive
sheets of large CD30+ cells. Usually denser than
that seen in LyP, the infiltrate reaches
the subcutaneous tissue. Most commonly, tumour
cells have features of anaplastic cells, showing
round, oval or irregularly shaped nuclei,
prominent eosinophilic nucleoli, and abundant
cytoplasm. Reactive small lymphocytes are often
present at the periphery of the lesion [2, 4-8]. The
histological differences between LyP type C and
C-ALCL are summarized in Table II.
Neoplastic cells in both LyP and C-ALCL
generally show the same phenotype of activated
CD4+ T lymphocytes with a variable loss
of CD2, CD5 and/or CD3. Rare cases (less than
5%) have a CD8+ T-cell phenotype and very
rarely cells are double negative (CD4-/CD8-).
C -ALCL is defined as showing expression
of CD30 in more than 75% of neoplastic cells.
Neoplastic cells in LPDs do not express epithelial
membrane antigen (EMA) and anaplastic
lymphoma kinase (ALK), in contrast to the often
positive staining in systemic anaplastic large cell
lymphoma. Unlike Hodgkin and Reed-Sternberg
cells in Hodgkin’s lymphoma, neoplastic cells in
LPD usually do not express CD15 [2-7, 9, 11, 14, 17].
Numerous histiocytes seen intermingled with
neoplastic cells have led in the past to erroneous
classification of C-ALCL as regressive atypical
histiocytosis [14].
The histological picture of the presented case
lies between C-ALCL and LyP type C. Sheets
of large atypical cells, the involvement
of the subcutaneous tissue in all the specimens,
morphology of these cells consistent with
anaplastic cells and a high mitotic index are closer
to the diagnosis of C-ALCL. Nevertheless,
the percentage of large cells expressing CD30 does
not reach 75%. No one has ever questioned these
criteria. Some authors have stressed
the importance of these quantitative criteria in
avoiding terminological confusion only, because
the similarity of cutaneous infiltrates in both LyP
and C-ALCL suggest that it would be better to
regard them as part of a continuous spectrum
of LPDs.
We have also observed in the reviewed
specimens small lymphocytes not only at
the periphery of the lesion, but also intermingled
with the infiltrate, which is a feature of LyP.
Moreover, clustering of the infiltrate around skin
adnexa, which was seen in the first three
specimens, is suggestive of LyP [1]. 
In the largest series of borderline cases (14 cases
from 84 LPDs), described by Paulli et al. [1],
the clinical presentation and prognosis were
similar to LyP. Probably for this reason some
authors include borderline cases in the category
of LyP (three cases from 43 LPDs [3]), or define
LyP type C as borderline cases [10]. Some authors
did not even find borderline cases in their material
(56 cases of LPDs [9] or 208 cases of LPDs [2]). For
the diagnosis of C-ALCL there should be no
clinical evidence or history of CTCL. It seems
that it should not apply to previous LPDs,
because the prognosis and clinical behaviour
of relapses in LyP, C-ALCL and C-ALCL
secondary to LyP are not different from those
characteristic of primary lesions [3, 9].
The majority of C-ALCL lesions and
approximately 60-70% of LyP lesions show clonal
rearrangement of T-cell receptor genes. The same
rearrangements have been shown in both LyP and
lymphomas secondary to LyP. The translocation
(2; 5) (p23; q35) and its variants was not
demonstrated in LyP, and was not or only rarely
found in C-ALCL [4, 6].
The differential diagnosis of LPDs includes
other types of lymphomas and also benign
conditions, which are listed in Table 3.
LyP has a favourable prognosis – the dise-
ase-free specific 5-year survival reaches 100%.
Nevertheless, 5-20% of patients develop other
cutaneous or nodal lymphomas – mycosis
fungoides, Hodgkin’s lymphoma, ALCL or
C-ALCL [4, 6, 9]. C-ALCL has a similar
favourable prognosis with a disease-free specific 
5-year survival reaching 90% [4, 6].
The choice of treatment is based on the size,
extent and clinical behaviour of the lesions. 
There is no available curative therapy of LyP
and no known therapy can alter the natural
history of LyP or lower the risk of developing
secondary lymphomas, with a possible exception
of preventing the progression to CD30+
lymphoma. Results of local-directed therapies in
C-ALCL (excision, radiotherapy+/-excision)
were similar to systemic chemotherapy (CHOP)
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with similar remission and relapse rates [9]. All
patients treated with chemotherapy (CHOP) with
multifocal lesions suffered from one or more skin
relapses. Relapses after systemic chemotherapy
occur also in LyP [2].
Most authors emphasize that differential
diagnosis between type C LyP and C-ALCL may
be difficult, if not impossible, but biological
differences between LyP and C-ALCL are not as
distinct as has been thought; relapses after
systemic chemotherapy occur in both lesions. It
seems likely that there are no strict boundaries
between the spectrum of LPDs, particularly
between C-ALCL and type C LyP [10].
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